Time is of the essence when it comes to stroke treatment

Time is of the essence when it comes to stroke treatment. But a new image guided technique could help shift the criterion from one that is determined by how long after the start of symptoms a patient receives medical care, suggests a small US study published online in the Journal of NeuroInterventional Surgery.

The researchers used computed tomography perfusion (CTP) to select 53 patients who would be suitable for interventional treatment, and found no difference in the recovery time or the 90 day survival rate between those whose symptoms had begun either less, or more, than six hours earlier.

Their findings lead them to conclude that the technique could enable more to be successfully treated, particularly those who live further away from specialist medical care.

"The application of this approach may have a significant impact on the number of patients eligible for beneficial interventional therapy, especially those initially presenting to rural or ," they conclude.

add to favorites email to friend print save as pdf

Related Stories

Arrival method, slow response often delay stroke care

Aug 08, 2008

Most stroke patients can't recall when their symptoms started or do not arrive at the hospital in a timely manner, so they cannot be considered for time-dependent therapies such as the clot-busting drug tissue plasminogen ...

Recommended for you

Validating maps of the brain's resting state

2 hours ago

Kick back and shut your eyes. Now stop thinking. You have just put your brain into what neuroscientists call its resting state. What the brain is doing when an individual is not focused on the outside world ...

User comments

More news stories

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...

Laughing gas does not increase heart attacks

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...